Opus Genetics, Inc. (NASDAQ:IRD) CEO Acquires $91,196.94 in Stock

Opus Genetics, Inc. (NASDAQ:IRDGet Free Report) CEO George Magrath acquired 90,294 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average price of $1.01 per share, with a total value of $91,196.94. Following the completion of the acquisition, the chief executive officer now owns 483,244 shares in the company, valued at $488,076.44. The trade was a 22.98 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

George Magrath also recently made the following trade(s):

  • On Monday, November 18th, George Magrath bought 9,706 shares of Opus Genetics stock. The stock was acquired at an average cost of $1.02 per share, with a total value of $9,900.12.

Opus Genetics Stock Down 3.0 %

Shares of NASDAQ IRD traded down $0.03 during trading on Tuesday, reaching $0.88. 243,421 shares of the company traded hands, compared to its average volume of 173,666. Opus Genetics, Inc. has a 52-week low of $0.85 and a 52-week high of $3.40.

Opus Genetics (NASDAQ:IRDGet Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The company had revenue of $3.87 million for the quarter, compared to the consensus estimate of $1.17 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. As a group, equities research analysts forecast that Opus Genetics, Inc. will post -1.22 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright initiated coverage on Opus Genetics in a report on Wednesday, November 13th. They set a “buy” rating and a $8.00 price target on the stock.

Read Our Latest Stock Report on IRD

Opus Genetics Company Profile

(Get Free Report)

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

Read More

Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.